Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Controlled Substances Scheduling topic
No spam. Unsubscribe anytime.
Committee introduces RS to reschedule multiple synthetic substances and add new prescription to Schedule IV
Summary
The House Health and Welfare Committee on Monday introduced RS 31,822, which would add dozens of synthetic illicit substances to Schedule I, reclassify synthetic anabolic steroids to Schedule III and add the newly FDA-approved drug zuranolone (Zirzuve) to Schedule IV.
The House Health and Welfare Committee introduced RS 31,822, a drafting request from the Idaho Board of Pharmacy to update the Idaho Uniform Controlled Substances Act by scheduling several synthetic and newly approved drugs. Nikki Chopsky, Health Professions Bureau Chief at the Division of Occupational and Professional Licenses and executive officer for the boards of Medicine, Nursing and Pharmacy, briefed the committee and asked that the RS be printed for a future bill hearing.
Chopsky summarized the proposal: "On pages 1 through 10, the bill adds 24 illicit substances that are either benzodiazepine derivatives, synthetic fentanyls, synthetic cannabinoids, or synthetic cathinones, also known as bath salts, to schedule 1." She said pages 12 and 13 propose moving "23 man made testosterone derivatives to schedule 3." On page 16, the RS would add zuranolone (branded Zirzuve), an FDA-approved treatment for postpartum depression, to Schedule IV.
Chopsky said the board discussed the proposed language at two public meetings beginning in September 2024, that no public feedback had been received to date, and that "we are not aware of any concerns with the proposed language." She also told the committee there is no expected fiscal impact to the general fund. Representative Healy moved to introduce RS 31,822; the committee voted by voice and the chair announced the motion carried.
If printed, the RS will be considered at a committee bill hearing where the committee may review statutory text and hear from law enforcement, medical professionals, pharmacists and other stakeholders about impacts, enforcement and implementation.
